

Rapid Case Review: Investigators Provide Perspectives on Actual Cases of Metastatic Bladder Cancer — Issue 3

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. What was the median number of cycles of enfortumab vedotin (EV) that patients received in the EV-302 study evaluating EV/pembrolizumab versus platinum-based chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma?
 - a. Three cycles
 - b. Six cycles
 - c. Nine cycles
 - d. Twelve cycles
2. What was the approximate 5-year overall survival rate reported with first-line EV/pembrolizumab for cisplatin-ineligible patients with advanced urothelial bladder cancer in the dose-escalation, cohort A portion of the EV-103 study?
 - a. 12%
 - b. 25%
 - c. 41%
 - d. 68%
3. Which of the following recommendations is current regarding assessment of nectin-4 expression levels in urothelial carcinoma?
 - a. Levels should be assessed by immunohistochemistry before initiation of EV
 - b. Levels should be assessed by FISH (fluorescence in situ hybridization) before initiation of EV
 - c. Levels should be assessed by next-generation sequencing before initiation of EV
 - d. Assessment of nectin-4 expression is not necessary before initiation of EV
4. What was the approximate rate of Grade ≥ 3 peripheral neuropathy (including both sensory and motor events) reported with EV/pembrolizumab in the EV-302 study?
 - a. 0%
 - b. 1% to 3%
 - c. 5% to 7%
 - d. 10% to 15%
 - e. 20% to 25%